For research use only. Not for therapeutic Use.
JMS-17-2 (CAT: I019017) is a compound that acts as a potent and selective antagonist of CX3CR1, which is the receptor for CX3CL1 (fractalkine). By specifically targeting CX3CR1, JMS-17-2 can inhibit the binding of CX3CL1 and disrupt downstream signaling pathways mediated by this receptor. CX3CR1 is known to play a role in various physiological and pathological processes, including immune cell trafficking and inflammation.
| Catalog Number | I019017 |
| CAS Number | 1380392-05-1 |
| Molecular Formula | C₂₅H₂₆ClN₃O |
| Purity | ≥95% |
| Target | CX3CR1 |
| Reference | [1]. Shen F, et al. Novel Small-Molecule CX3CR1 Antagonist Impairs Metastatic Seeding and Colonization of Breast Cancer Cells. Mol Cancer Res. 2016 Jun;14(6):518-27. |
